Cellnovo Appoints John Brooks as Chairman of the Board of Directors

Regulatory News:

Cellnovo Group (Paris:CLNV) ("Cellnovo” CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, is pleased to announce the appointment of John Brooks as Chairman of the Board.

A recognised leader in the healthcare industry, John Brooks has more than 20 years’ experience in the field of diabetes, beginning when his son was diagnosed with the condition, inspiring him to co-found Insulet, the company behind Omnipod, a tubeless insulin-pump system for type 1 diabetes. Today, Insulet is a global business with a market capitalisation of $1.8 billion. Leveraging this experience, Mr. Brooks will play an important role in the advancement of Cellnovo’s strategy to develop and internationally commercialise its unique diabetes management system.

More recently, Mr. Brooks was President and Chief Executive Officer of the Joslin Diabetes Center, which is affiliated with the Harvard Medical School from 2011 to 2015. Before his appointment as President and Chief Executive Officer, he served on the Board for eight years, two as Chairman, where he played an integral role. Mr. Brooks also was previously CEO of Reflectance Medical from 2009 to 2015, which offers technology for non-invasive monitoring of critically ill patients.

Currently, Mr. Brooks is Chief Executive Officer of Arete Worldwide, a consulting company which accelerates the development of innovative solutions for the treatment of obesity, including patients with diabetes. Mr. Brooks is also a consultant at Healthcare Capital Consulting LLC, which advises early-stage life sciences companies.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: "I am delighted to welcome John Brooks as Chairman. John has unrivaled experience in diabetes and the broader healthcare sector and his appointment as Chairman of the Board will prove invaluable to the Company as we continue to progress the development and international commercialization of our unique diabetes management system.”

John Brooks, Chairman of Cellnovo, added: "I am very excited to be joining Cellnovo at this pivotal point in the Company’s development. I believe Cellnovo’s unique approach to diabetes management has enormous potential and I look forward to working with the Cellnovo team to bring this next generation product to more patients globally.”

------

In the coming months, Cellnovo will participate in the following investor events:

• Healthcare Forum – Société Générale, June 28, Paris

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real-time.

Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV

View source version on businesswire.com: http://www.businesswire.com/news/home/20160609005870/en/